Pretreatment with ATL146e prevents pulmonary dysfunction in NY1DD-Rag1−/− mice after the adoptive transfer of vehicle-treated but not FSPTP-pretreated NKT cells
| Cells (105) . | (a) NY1DD (n = 8) . | (b) NY1DD-Rag1−/− (n = 8) . | (c) NY1DD-Rag1−/− + NKT cells (n = 4) . | (d) NY1DD-Rag1−/− + ATL146e + NKT cells (n = 4) . | (e) NY1DD-Rag1−/− + ATL146e + SPTP NKT cells (n = 4) . |
|---|---|---|---|---|---|
| NK | 4.30 (0.85) | 6.71 (1.28)* | 12.32 (1.03)*,** | 2.80 (1.00)*** | 2.63 (0.77)*** |
| PMNs | 2.34 (0.40) | 1.63 (0.46) | 6.64 (1.90)*,** | 1.23 (0.58)*** | 6.85 (1.34)*,# |
| iNKT | 0.37 (0.06) | n/a | 0.46 (0.12) | 0.15 (0.04) | 0.63 (0.16)# |
| Cells (105) . | (a) NY1DD (n = 8) . | (b) NY1DD-Rag1−/− (n = 8) . | (c) NY1DD-Rag1−/− + NKT cells (n = 4) . | (d) NY1DD-Rag1−/− + ATL146e + NKT cells (n = 4) . | (e) NY1DD-Rag1−/− + ATL146e + SPTP NKT cells (n = 4) . |
|---|---|---|---|---|---|
| NK | 4.30 (0.85) | 6.71 (1.28)* | 12.32 (1.03)*,** | 2.80 (1.00)*** | 2.63 (0.77)*** |
| PMNs | 2.34 (0.40) | 1.63 (0.46) | 6.64 (1.90)*,** | 1.23 (0.58)*** | 6.85 (1.34)*,# |
| iNKT | 0.37 (0.06) | n/a | 0.46 (0.12) | 0.15 (0.04) | 0.63 (0.16)# |
NY1DD × Rag1−/− mice were pre-treated with ATL146e (10 ng/kg/minute, 3 days). On day 2, 106 NKT cells pretreated in vitro with vehicle or FSPTP were adoptively transferred. On day 3, pulmonary leukocytes were analyzed by FACS. Data are means ± SEM and were analyzed by 1-way ANOVA with Neuman-Keuls posttesting.
P < .05 vs a.
P < .05 vs b.
P < .05 vs c.
P < .05 vs d.